MedPath

Investigation of tolerablity & effectiveness of Bromocriptine in comparison with Teneligliptin in patients diagnosed with type II diabetes mellitus

Not Applicable
Conditions
Health Condition 1: null- type 2 diabetes mellitusHealth Condition 2: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2018/05/013591
Lead Sponsor
asrin Nisha
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Newly diagnosed type 2 DM

FBS between 140 mg/dl and 240 mg/dl

PPBS between 200 mg/dl and 350 mg/dl

Hb1Ac between 7% &10%

BMI between 22 and 40 kg/m2

Exclusion Criteria

Patients with complications of DM

Pregnant & nursing women

Patients with known hypersensitivity to Bromocriptine or ergot related compounds or Teneligliptin.

Patients with migraine.

Patients with H/O significant systemic disorders

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath